TrialJournal for immunotherapy of cancer2021

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.

Leonie K de Klerk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.